“Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies because of a high number of unmet needs for improved treatments in different types of cancer. In 2009, around 40,000 Phase I, II and III trials were listed on ClinicalTrials.gov, and approximately 40% of these were related to cancer.” – Source Business Insights
This presentation will give a market overview: which drugs are in development for which cancers; what are the areas of unmet need; and which contract research organizations (CROs) lead the field.
- Who’s developing what for which cancers
- Pipeline opportunities – what are the unmet needs in oncology
- Profiles of the leading CROs in the oncology trial services sector
- How use of CROs can help overcome the unique challenges in oncology development
Gareth Macdonald, Senior Editor, Outsourcing-Pharma.com
Eric Bolesh, Research Director, Cutting Edge Information